---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-015648"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:10:15.924941+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused

## Summary
- Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.
- No improvement on primary efficacy measure MDS-UPDRS Parts 2+3 at any dose vs placebo.
- Secondary signals: Part 2 improved -1.41 at 100 mg (p=0.036); Schwab & England +4% at 50 mg (p=0.0004).
- Skin biopsy analysis suggests treatment-dependent reduction in neuronal alpha-synuclein deposition.
- Company pausing risvodetinib to focus resources on IkT-001Pro for PAH; evaluating strategic options.

## SEC filing metadata
- accession: 0001193125-25-015648
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/0001193125-25-015648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525015648/d919757d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-015648
- JSON: https://secwatch.observer/filing/0001193125-25-015648.json
- Plain text: https://secwatch.observer/filing/0001193125-25-015648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.